Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Viking Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -34.83%. The profit margin, also known as the revenue ratio or gross profit ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

On Thursday, Viking Therapeutics (NASDAQ:VKTX) received a favorable initiation of coverage from Jefferies, with a Buy rating and a price target set at $110.00. The... Biotech firm Viking ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street’s main indices finished firmer on Friday, with all main ...